Literature DB >> 24866199

Rituximab: how approval history is reflected by a corresponding patent filing strategy.

Ulrich Storz1.   

Abstract

Because drug development is not a static process, a drug's market authorisation may change over time. In many cases, the number of indications for which a drug is approved increases. Because this facet of drug development also comes at significant costs, a corresponding patent filing strategy is required to protect these investments. The strategy as applied to rituximab, which is approved for a variety of indications, is discussed in this review.

Entities:  

Keywords:  antibody; authorisation; patent; rituximab; strategy

Mesh：

Substances：

Year:  2014        PMID： 24866199      PMCID： PMC4171018          DOI： 10.4161/mabs.29105

Source DB:  PubMed          Journal:  MAbs        ISSN： 1942-0862            Impact factor:   5.857


  14 in total

1.  Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.

Authors:  Mark S Cragg; Suzanne M Morgan; H T Claude Chan; B Paul Morgan; A V Filatov; Peter W M Johnson; Ruth R French; Martin J Glennie
Journal:  Blood       Date:  2002-09-19       Impact factor: 22.113

Review 2.  The Cabilly patents: status quo and relevance for antibody companies.

Authors:  Ulrich Storz
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

3.  Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope.

Authors:  Colin G Sandercock; Ulrich Storz
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

4.  The market for follow-on biologics: how will it evolve?

Authors:  Henry Grabowski; Iain Cockburn; Genia Long
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

5.  Off-label use of rituximab in a multipayer insurance system.

Authors:  Eliezer M Van Allen; Todd Miyake; Nathan Gunn; Caroline M Behler; Jeff Kohlwes
Journal:  J Oncol Pract       Date:  2011-03       Impact factor: 3.840

6.  Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.

Authors:  L M Nadler; P Stashenko; R Hardy; W D Kaplan; L N Button; D W Kufe; K H Antman; S F Schlossman
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

Review 7.  Novel CD20 monoclonal antibodies for lymphoma therapy.

Authors:  Shundong Cang; Nikhil Mukhi; Kemeng Wang; Delong Liu
Journal:  J Hematol Oncol       Date:  2012-10-11       Impact factor: 17.388

8.  Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity.

Authors:  Dominika Rudnicka; Anna Oszmiana; Donna K Finch; Ian Strickland; Darren J Schofield; David C Lowe; Matthew A Sleeman; Daniel M Davis
Journal:  Blood       Date:  2013-04-23       Impact factor: 22.113

9.  Off-label use of rituximab in dermatology: pemphigus treatment.

Authors:  Lislaine Bomm; Tainá Scalfoni Fracaroli; João Luz Sodré; Aline Bressan; Alexandre Carlos Gripp
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896

10.  Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.

Authors:  Alain Beck; Janice M Reichert
Journal:  MAbs       Date:  2013-07-24       Impact factor: 5.857
View more
  8 in total

1.  Antibody-drug conjugates: Intellectual property considerations.

Authors:  Ulrich Storz
Journal:  MAbs       Date:  2015-08-20       Impact factor: 5.857

Review 2.  2021 update on thyroid-associated ophthalmopathy.

Authors:  E J Neag; T J Smith
Journal:  J Endocrinol Invest       Date:  2021-08-20       Impact factor: 5.467

3.  Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?

Authors:  Terry J Smith
Journal:  Expert Opin Orphan Drugs       Date:  2018-09-26       Impact factor: 0.694

Review 4.  Drug repurposing: progress, challenges and recommendations.

Authors:  Sudeep Pushpakom; Francesco Iorio; Patrick A Eyers; K Jane Escott; Shirley Hopper; Andrew Wells; Andrew Doig; Tim Guilliams; Joanna Latimer; Christine McNamee; Alan Norris; Philippe Sanseau; David Cavalla; Munir Pirmohamed
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

Review 5.  Current progress in innovative engineered antibodies.

Authors:  William R Strohl
Journal:  Protein Cell       Date:  2017-08-18       Impact factor: 14.870

6.  Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.

Authors:  Matthias B Moor; Franziska Suter-Riniker; Michael P Horn; Daniel Aeberli; Jennifer Amsler; Burkhard Möller; Linet M Njue; Cesare Medri; Anne Angelillo-Scherrer; Luca Borradori; Susanne Radonjic-Hoesli; S Morteza Seyed Jafari; Andrew Chan; Robert Hoepner; Vera Ulrike Bacher; Laila-Yasmin Mani; Joseena Mariam Iype; Cédric Hirzel; Britta Maurer; Daniel Sidler
Journal:  Lancet Rheumatol       Date:  2021-09-07

7.  A Case of Rituximab-Induced Acute Thrombocytopenia in a Patient with Splenic Marginal Zone Lymphoma and Chronic Hepatitis C Virus Infection.

Authors:  Aref Qureini; Samia Asif; Stephanie Harry; Sheshadri Madhusudhana
Journal:  Am J Case Rep       Date:  2019-09-21

8.  An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?

Authors:  Evelien Moorkens; Arnold G Vulto; Isabelle Huys
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.